Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1839154 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL11902437 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL14550059 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL1839151 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL4209759 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL34467094 | 0.87 | MAPT (0.53) | SLC9A1FFAR1MAPTGAAHPGD | |
| SCHEMBL16232154 | 0.84 | SLC9A1 (0.60) | SLC9A1HRH3KDM1ASIGMAR1MAPT | |
| SCHEMBL17189659 | 0.84 | SLC9A1 (0.65) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL13976000 | 0.84 | SLC9A1 (0.65) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL12765396 | 0.84 | SLC9A1 (0.60) | SLC9A1HRH3KDM1ASIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115084520-B | Alkali metal negative electrode surface treatment liquid composition and application thereof | 厦门大学 | 2024-01-12 | — | — | CN | claimed |
| CN-115084520-A | Alkali metal negative electrode surface treatment liquid composition and application thereof | 厦门大学 | 2022-09-20 | — | — | CN | claimed |
| EP-2742029-B1 | N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | claimed |
| US-8912202-B2 | N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | claimed |
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | claimed |
| EP-2742029-A1 | N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS | Merck Patent GmbH (DE) | 2014-06-18 | — | — | EP | claimed |
| WO-2013020622-A1 | N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS | MERCK PATENT GMBH (DE) | 2013-02-14 | — | — | WO | claimed |
| US-20090036473-A1 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-02-05 | — | — | US | claimed |
| EP-1996560-A1 | QUINAZOLINONES AND THEIR USE AS POTASSIUM CHANNELS ACTIVATORS | NeuroSearch A/S (DK) | 2008-12-03 | — | — | EP | claimed |
| EP-1585749-B1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007104717-A1 | QUINAZOLINONES AND THEIR USE AS POTASSIUM CHANNELS ACTIVATORS | NEUROSEARCH A/S (DK) | 2007-09-20 | — | — | WO | claimed |
| EP-1565190-A4 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL MYERS SQUIBB CO (US) | 2006-04-26 | — | — | EP | claimed |
| EP-1565190-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2004047738-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | claimed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2004063198-A1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004047738-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | LPAR5, LPAR2, LPAR1 | SLC9A1 4163/4885FFAR1 85/4885HRH3 685/4885 |
| US-20090036473-A1 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | KCNK17, KCNN3, KCNA7 | SLC9A1 263/4885FFAR1 2816/4885HRH3 1085/4885 |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | SLC9A1 2273/4885FFAR1 2784/4885HRH3 2567/4885 |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | KCNQ2, KCNQ5, KCNJ2 | SLC9A1 403/4885FFAR1 130/4885HRH3 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.